Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 19/20 | 1.00 |
| ▸ | RAB9A | P51151 | 19/20 | 1.00 |
| ▸ | CASP3 | P42574 | 2/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.71 |
| ▸ | RELA | Q04206 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110447 | 0.86 | NPC1 (1.00) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL31054230 | 0.84 | NPC1 (1.00) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL4115937 | 0.84 | NPC1 (1.00) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL14014122 | 0.82 | NPC1 (1.00) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL30851500 | 0.82 | RAB9A (0.79) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL27193042 | 0.82 | RAB9A (0.79) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL4118296 | 0.82 | NPC1 (0.75) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL4548183 | 0.82 | RAB9A (0.69) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL6702838 | 0.82 | NPC1 (0.67) | NPC1RAB9ACASP3SENP7KMT2A | |
| SCHEMBL8126912 | 0.81 | RAB9A (0.68) | NPC1RAB9ACASP3SENP7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | NPC1 927/4885RAB9A 815/4885CASP3 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.